tradingkey.logo

60 Degrees Pharmaceuticals Inc

SXTP
0.689USD
-0.049-6.65%
收盘 12/24, 13:00美东报价延迟15分钟
2.83M总市值
亏损市盈率 TTM

60 Degrees Pharmaceuticals Inc

0.689
-0.049-6.65%

关于 60 Degrees Pharmaceuticals Inc 公司

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

60 Degrees Pharmaceuticals Inc简介

公司代码SXTP
公司名称60 Degrees Pharmaceuticals Inc
上市日期Jul 12, 2023
CEODow (Geoffrey S)
员工数量3
证券类型Ordinary Share
年结日Jul 12
公司地址1025 Connecticut Avenue Nw
城市WASHINGTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编20036
电话12023275422
网址https://60degreespharma.com/
公司代码SXTP
上市日期Jul 12, 2023
CEODow (Geoffrey S)

60 Degrees Pharmaceuticals Inc公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Geoffrey S. Dow, Ph.D.
Dr. Geoffrey S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
22.79K
+46.19%
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
15.82K
+79.40%
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
5.27K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Commercial Officer
Chief Commercial Officer
4.54K
--
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
234.00
--
Mr. Paul Field
Mr. Paul Field
Independent Director
Independent Director
234.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
234.00
--
Mr. Patrick Gaynes
Mr. Patrick Gaynes
Investor Relations Officer
Investor Relations Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Geoffrey S. Dow, Ph.D.
Dr. Geoffrey S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
22.79K
+46.19%
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
15.82K
+79.40%
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
5.27K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Commercial Officer
Chief Commercial Officer
4.54K
--
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
234.00
--
Mr. Paul Field
Mr. Paul Field
Independent Director
Independent Director
234.00
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Orca Capital GmbH
3.93%
Dow (Geoffrey S)
1.07%
Knight Therapeutics, Inc.
0.80%
DRW Securities, LLC
0.60%
Xu (Cheryl)
0.37%
其他
93.23%
持股股东
持股股东
占比
Orca Capital GmbH
3.93%
Dow (Geoffrey S)
1.07%
Knight Therapeutics, Inc.
0.80%
DRW Securities, LLC
0.60%
Xu (Cheryl)
0.37%
其他
93.23%
股东类型
持股股东
占比
Investment Advisor
4.53%
Individual Investor
1.70%
Corporation
0.80%
Investment Advisor/Hedge Fund
0.29%
Hedge Fund
0.07%
Bank and Trust
0.03%
其他
92.57%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
22
451.55K
11.00%
+385.44K
2025Q2
28
103.95K
3.22%
+2.41K
2025Q1
28
93.99K
6.38%
-12.96K
2024Q4
26
104.62K
14.10%
+11.58K
2024Q3
25
101.03K
25.05%
+54.30K
2024Q2
23
54.29K
27.13%
-3.10K
2024Q1
19
57.35K
31.08%
+1.78K
2023Q4
19
60.17K
63.69%
+30.80K
2023Q3
18
63.13K
66.75%
+44.65K

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Orca Capital GmbH
166.23K
4.05%
+166.23K
--
Jul 16, 2025
Dow (Geoffrey S)
22.79K
0.56%
+7.20K
+46.19%
Sep 12, 2025
Knight Therapeutics, Inc.
33.90K
0.83%
+14.67K
+76.26%
Sep 30, 2024
Xu (Cheryl)
15.82K
0.39%
+7.00K
+79.40%
Aug 26, 2025
Geode Capital Management, L.L.C.
12.52K
0.3%
+592.00
+4.96%
Jun 30, 2025
Miller (Tyrone)
5.27K
0.13%
--
--
Aug 26, 2025
Landon (Kristen)
4.54K
0.11%
--
--
Aug 26, 2025
Tower Research Capital LLC
2.60K
0.06%
+1.05K
+67.61%
Jun 30, 2025
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
公告日期
类型
比率
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1

常见问题

60 Degrees Pharmaceuticals Inc的前五大股东是谁?

60 Degrees Pharmaceuticals Inc 的前五大股东如下:
Orca Capital GmbH持有股份:166.23K,占总股份比例:4.05%。
Dow (Geoffrey S)持有股份:22.79K,占总股份比例:0.56%。
Knight Therapeutics, Inc.持有股份:33.90K,占总股份比例:0.83%。
Xu (Cheryl)持有股份:15.82K,占总股份比例:0.39%。
Geode Capital Management, L.L.C.持有股份:12.52K,占总股份比例:0.30%。

60 Degrees Pharmaceuticals Inc的前三大股东类型是什么?

60 Degrees Pharmaceuticals Inc 的前三大股东类型分别是:
Orca Capital GmbH
Dow (Geoffrey S)
Knight Therapeutics, Inc.

有多少机构持有60 Degrees Pharmaceuticals Inc(SXTP)的股份?

截至2025Q3,共有22家机构持有60 Degrees Pharmaceuticals Inc的股份,合计持有的股份价值约为451.55K,占公司总股份的11.00%。与2025Q2相比,机构持股有所增加,增幅为7.78%。

哪个业务部门对60 Degrees Pharmaceuticals Inc的收入贡献最大?

在--,--业务部门对60 Degrees Pharmaceuticals Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI